# A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

> **NCT05329259** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 200 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT05329259
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329259, "A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05329259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*